ClinicalTrials.gg

Program

Palopegteriparatide

Also written as “TransCon PTH” and “Palopegteriparatide Experimental Arm”.

Its studies are mostly in Hypoparathyroidism, led by 3 companies.

Furthest: phase 3, since Jun 23, 20265 company-led studies, 2 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ascendis Pharma21 open or runningphase 3since Jun 23, 2026Jun 20, 2019Aug 2027phase 3 · NCT07706764
Ascendis Pharma Bone Diseases21 open or runningphase 3since Jan 6, 2021Jan 6, 2021Jun 2027phase 3 · NCT07081997
Visen Pharmaceuticals (Shanghai)10 open or runningphase 3since May 18, 2022May 18, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 20, 2019First study: phase 2 study in HypoparathyroidismNew to Ascendis PharmaAscendis Pharma · NCT04009291 · 59 enrolled · United States, Canada, Denmark and more
  2. Jan 6, 2021Ascendis Pharma Bone Diseases’ first study: phase 3 study in HypoparathyroidismNew to Ascendis Pharma Bone DiseasesAscendis Pharma Bone Diseases · NCT04701203 · 84 enrolled · United States, Canada, Denmark and more
  3. May 18, 2022Visen Pharmaceuticals (Shanghai)’s first study: phase 3 study in HypoparathyroidismNew to Visen Pharmaceuticals (Shanghai)Visen Pharmaceuticals (Shanghai) · NCT05387070 · 81 enrolled · China
  4. Jul 22, 2025Phase 3 study in HypoparathyroidismAscendis Pharma Bone Diseases · NCT07081997 · 36 planned · United States
  5. Jun 23, 2026Phase 3 study in HypoparathyroidismPhase 3 reachedAscendis Pharma · NCT07706764 · 12 planned · France, Poland

Ahead

  1. Jun 2027Primary completion: phase 3 study in HypoparathyroidismAscendis Pharma Bone Diseases · NCT07081997
  2. Aug 2027Primary completion: phase 3 study in HypoparathyroidismAscendis Pharma · NCT07706764

TargetBeta

PTH1R →read by rule
“Parathyroid hormone receptor agonist; Parathyroid hormone receptor agonist”ChEMBL 37, by rule

Other programs on PTH1R

ProgramCompanyFurthest phaseStudies
eneboparatideAstraZenecaphase 32

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07706764Hypoparathyroidism · France, Poland3RecruitingAscendis PharmaAug 202712
NCT07081997Hypoparathyroidism · United States3RecruitingAscendis Pharma Bone DiseasesJun 202736
NCT05387070Hypoparathyroidism · China3CompletedVisen Pharmaceuticals (Shanghai)Jan 4, 202381
NCT04701203Hypoparathyroidism · United States, Canada, Denmark and more3CompletedAscendis Pharma Bone DiseasesJan 12, 202284
NCT04009291Hypoparathyroidism · United States, Canada, Denmark and more2CompletedAscendis PharmaMar 6, 202059

How it is read

Names in the registry

  • “TransCon PTH”, 3 entries
  • “Palopegteriparatide Experimental Arm”, 1 entry
  • “Palopegteriparatide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.